对大粒状淋巴细胞白血病治疗结果的分析:印度的一项回顾性研究
Mir Sadaqat Hassan Zafar1, Sajad Ahmad Geelani2, Javid Rasool Bhat2
1Department of Clinical Hematology, Super Speciality Hospital, Srinagar, Jammu and Kashmir, India.
South Asian journal of cancer
|December 25, 2025
概括
大颗粒性淋巴细胞 (LGL) 白血病是一种罕见的T细胞或NK细胞瘤,在免疫抑制疗法中显示出有前途的结果. 这项研究发现,LGL白血病患者的整体治疗响应率为83.33%.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 大粒状淋巴细胞白血病 (LGL) 是一种罕见的,惰的淋巴增殖性疾病,被归类为成熟的T细胞和自然杀手细胞 (NK) 瘤.
- 了解治疗疗效对于管理这种不常见的疾病至关重要.
研究的目的:
- 评估诊断为LGL白血病的患者免疫抑制疗法的应答率.
- 分析LGL白血病病例的临床表现和治疗结果.
主要方法:
- 从两个三级保健机构对慢性淋巴增殖性疾病 (CLPD) 的回顾性分析.
- 根据世卫组织的分类,对14例LGL白血病确诊病例的鉴定和亚分析.
- 评估表现特征和对免疫抑制治疗的反应.
主要成果:
- 确定了14例LGL白血病 (3.64%的CLPD),主要是T-LGL类型 (92.85%).
- 常见的表现包括贫血 (92.85%),淋巴细胞症 (85.71%) 和中性衰竭 (78.57%).
- 观察到总体治疗响应率为83.33%,其中35.71%实现完全缓解,35.71%实现部分缓解.
结论:
- 免疫抑制疗法在治疗LGL白血病方面表现出极好的反应率.
- 这种治疗方法为这种罕见的淋巴增殖性疾病提供了可行的治疗选择.
更多相关视频
10:26Assessment of Mitochondrial Health in Cancer-Associated Fibroblasts Isolated from 3D Multicellular Lung Tumor Spheroids
Published on: October 21, 2022
2.4K
09:07Author Spotlight: Accelerating Diagnostic Accuracy with Direct Identification of Gram-Negatives from Blood Culture Bottles
Published on: May 24, 2024
1.4K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...